In conclusion, we revealed that low expression of MxA correlated with better survival in GBM patients receiving HSPPC-96 vaccination, indicating that MxA is a potential biomarker for the pre-vaccination recognition of responsive patients to this immunotherapy. The gene discussed is MX1; the disease is glioblastoma.